Search results for "infusion"

showing 10 items of 233 documents

Rituximab in refractory pemphigus vulgaris

2008

Pemphigus vulgaris (PV) is a severe chronic autoimmune blistering disease of skin and mucous membranes. The use of systemic corticosteroids in pemphigus has dramatically reduced its mortality rate, but the long-term use of steroids leads to severe side effects, many of which are serious. For this reason it is often necessary to add immunosuppressive agents to the regimen. However, there are occasional refractory cases in which therapy with conventionally accepted modalities is either not efficacious or not possible on account of side effects. Rituximab is a therapeutic monoclonal antibody targeting CD20, an integral membrane protein highly expressed on the surface of pre-B lymphocytes and a…

Adultmedicine.medical_specialtyAntigens CD19B-Lymphocyte SubsetsDrug ResistanceDermatologyDrug Administration ScheduleAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRituximab pemphigus vulgarisimmune system diseasesHumansImmunologic FactorsMedicineInfusions IntravenousCD20integumentary systembiologybusiness.industryRemission InductionPemphigus vulgarisAntibodies MonoclonalGeneral MedicineAntigens CD20medicine.diseaseDermatologyRegimenPemphigusMonoclonalImmunologybiology.proteinPrednisoneDrug Therapy CombinationFemaleRituximabRituximabbusinessImmunosuppressive AgentsPemphigusmedicine.drugDermatologic Therapy
researchProduct

Cost analysis of target-controlled infusion-based anesthesia compared with standard anesthesia regimens.

2000

UNLABELLED With the development of new computer-assisted target-controlled infusion (TCI) systems and the availability of short-acting anesthetics, total IV anesthesia (TIVA) has become increasingly popular. The aim of this study was to compare costs of TCI-based anesthesia with two standard anesthesia regimens. Sixty patients undergoing elective laparoscopic cholecystectomy were randomly divided into three groups. Group 1 (TIVA/TCI) received TIVA using a propofol-based TCI system and continuous administration of remifentanil; Group 2 (isoflurane) underwent inhaled anesthesia with isoflurane, fentanyl, and N2O; Group 3 (standard propofol) received fentanyl and N2O and a continuous infusion …

Adultmedicine.medical_specialtyCost-Benefit AnalysisRemifentanilAnesthesia GeneralFentanylPacuRemifentanilDrug Delivery SystemsPiperidinesMedicineHumansInfusions IntravenousPropofolInfusion PumpsAgedbiologyIsofluranebusiness.industryMiddle Agedbiology.organism_classificationSurgeryFentanylRegimenAnesthesiology and Pain MedicineIsofluraneAnesthesiaAnestheticAnesthetics Inhalationmedicine.symptombusinessPropofolPostoperative nausea and vomitingAnesthetics Intravenousmedicine.drugAnesthesia and analgesia
researchProduct

A Phase II Trial of Mitoxantrone plus Cyclophosphamide and 5-Fluorouracil in Modulation with Levo-Folinate for Advanced Breast Cancer Patients

1995

Advanced breast cancer remains a major clinical problem. Current chemotherapy regimens are able to induce a clinical response in many patients but do not appear to influence significantly patients' survival. The use of new drugs such as mitoxantrone with a predicted lower toxicity and biochemical modulation of 5-fluorouracil with levo-folinate are extensively studied research areas that could combine good therapeutic efficacy with the maintenance of an acceptable quality of life. 34 patients with advanced breast carcinoma were included in the study. Only 4 women had received prior chemotherapy for advanced disease. Treatment plan was: 5-fluorouracil 400 mg/m2 + l-leucovorin 100 mg/m2 days 1…

Adultmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentLeucovorinBreast NeoplasmsGastroenterologyDrug Administration ScheduleInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansPharmacology (medical)Neoplasm MetastasisInfusions IntravenousCyclophosphamideAgedAntibacterial agentPharmacologyMitoxantroneCardiotoxicityChemotherapyLeukopeniaDose-Response Relationship Drugbusiness.industryMiddle AgedSurgeryInfectious DiseasesOncologyFluorouracilToxicityFemaleFluorouracilMitoxantronemedicine.symptombusinessmedicine.drugJournal of Chemotherapy
researchProduct

Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a G…

2011

Objectives: The objective of the study was to assess the feasibility, toxicity, and reasons for early discontinuation of a modified outpatient intraperitoneal/intravenous (IP/IV) chemotherapy regimen for the treatment of patients with optimally debulked stage III ovarian cancer. Methods: Between February 2006 and November 2008, 51 consecutive patients from Institutions of the Spanish Ovarian Cancer Group (GEICO) were treated with a modified outpatient IP chemotherapy regimen. Patients received IV paclitaxel 175 mg/m2 over 3 hours on day 1, followed by IP cisplatin 100 mg/m2 (or 75 mg/m2 according to the principal investigator9s criteria) on day 2. On day 8, patients received IP paclitaxel 6…

Adultmedicine.medical_specialtyPaclitaxelmedicine.medical_treatmentNeutropeniaCarcinoma Ovarian EpithelialDrug Administration ScheduleAntineoplastic Combined Chemotherapy ProtocolsOutpatientsMedicineHumansInfusions ParenteralNeoplasms Glandular and EpithelialProspective StudiesProspective cohort studyInfusions IntravenousAgedNeoplasm StagingStage III Ovarian CancerOvarian NeoplasmsChemotherapybusiness.industryObstetrics and GynecologyMiddle Agedmedicine.diseaseChemotherapy regimenSurgeryClinical trialRegimenTreatment OutcomeOncologySpainFeasibility StudiesFemaleCisplatinbusinessOvarian cancerInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
researchProduct

Tolerability and efficacy of high-dose furosemide and small-volume hypertonic saline solution in refractory congestive heart failure

2000

Thirty patients aged 65-85 years, with refractory New York Heart Association (NYHA) class IV congestive heart failure (CHF) were treated with an intravenous infusion of furosemide (250-2000 mg/d) and small-volume hypertonic saline solution (150 mL of 1.4-4.6% NaCl) twice a day for 6 to 12 days. A daily fluid oral intake of 1000 mL and previous cardiac therapy were maintained. Clinical signs and symptoms of CHF, such as dyspnea, edema and weakness, improved, as did severity of illness as defined by NYHA class. The infusion was well tolerated. After a 12-month follow-up, 24 patients (80%) were alive and in the NYHA class assigned on discharge from the hospital. This therapeutic combination is…

Aged 80 and overHeart FailureMaleSaline Solution HypertonicAged; Aged 80 and over; Diuretics; Female; Furosemide; Heart Failure; Humans; Infusions Intravenous; Italy; Male; Saline Solution Hypertonic; Statistics Nonparametric; Survival RateStatistics NonparametricSurvival RateItalyFurosemideDiureticHumansFemaleInfusions IntravenouDiureticsInfusions IntravenousHumanAged
researchProduct

Calculation of the pH and the titratable acidity in clinically used infusion solutions.

2006

Clinically used infusion solutions are complex aqueous mixtures composed of a variety of different salts, acids, and non-electrolytes, and are characterized by composition, initial pH, and titratable acidity (TA). By rigorous treatment as a multi-composed acid-base system, pH and TA were calculated from proton dissociation equilibria, mass balance equations and electroneutrality condition. Nine were arbitrarily chosen as model solutions in which pH and TA were experimentally determined. From composition, and based on a set of apparent acidity constants (pK values) at 37 degrees C and total ionic strength 0.155 mol/l, pH was calculated by iteration. In the model solutions, measured pH was in…

Aqueous solutionChemistryMass balanceProton dissociationAnalytical chemistryTitrimetryHealth InformaticsTitratable acidHydrogen-Ion ConcentrationMean differenceComputer Science ApplicationsBody FluidsFluid therapyModels ChemicalIonic strengthBiomimetic MaterialsFluid TherapyComposition (visual arts)Computer SimulationInfusions ParenteralInfusions IntravenousSoftwareComputer methods and programs in biomedicine
researchProduct

Association Between Implementation of the Athlete Biological Passport and Female Elite Runners’ Performance

2020

The purpose of this research was to evaluate the performances of female middle- and long-distance runners before and after the implementation of a new antidoping strategy (the Athlete Biological Passport [ABP]) in a country accused of systematic doping. A retrospective analysis of the results of Russian National Championships from 2008 to 2017 was performed. The 8 best female performances for the 800-m, 1500-m, 3000-m steeplechase, 5000-m, and 10,000-m events from the semifinals and finals were analyzed. The yearly number of athletes fulfilling standard qualifications for international competitions was also evaluated. Overall, numbers of athletes banned for doping in 2008–2017 were calculat…

BLOODPhysical Therapy Sports Therapy and RehabilitationMaailman antidopingtoimistodopingantidoping01 natural sciences03 medical and health sciences0302 clinical medicineBlood dopingurheiluRetrospective analysisMedicineOrthopedics and Sports Medicine315 Sport and fitness sciencesbiologybusiness.industryAthletesWorld Anti-Doping Agency010401 analytical chemistryINFUSIONveri1184 Genetics developmental biology physiologyblood doping030229 sport sciencesbiology.organism_classificationhuippu-urheilu0104 chemical sciencesdoping in sportsbusinessDemography
researchProduct

Acute changes of systemic parameters in tumour-bearing rats, and of tumour glucose, lactate, and ATP levels upon local hyperthermia and/or hyperglyca…

1991

Arterial blood pressure and relevant parameters of the arterial blood (O2 and CO2 tensions, pH, haematocrit, serum electrolytes and osmolality) were determined in tumour-bearing rats upon local hyperthermia (HT) and/or hyperglycaemia (HG). Tumour heating was performed in a saline bath (44 degrees C) for 120 min; hyperglycaemia was induced by i.v. infusion of 40% glucose solution for 150 min [blood glucose levels: 35-40 mM during heating; total amount of glucose: 1.19 g/100 g body wt.; infusion rates: 0.31 ml (100 g body wt.)-1 min-1 for 2 min, 0.02 ml (100 g body wt.)-1 min-1 for 88 min, and 0.01 ml (100 g body wt.)-1 min-1 for 60 min]. Immediately after treatment, glucose, lactate and ATP …

Blood GlucoseMaleHyperthermiaCancer Researchmedicine.medical_specialtyPartial Pressuremedicine.medical_treatmentHemodynamicsBlood PressureStimulationElectrolytesAdenosine TriphosphateInternal medicinemedicineAnimalsLactic AcidInfusions IntravenousSalineHematologyChemistryMusclesOsmolar ConcentrationRats Inbred StrainsHyperthermia InducedNeoplasms ExperimentalGeneral MedicineMetabolismCarbon DioxideHydrogen-Ion Concentrationmedicine.diseaseCombined Modality TherapyRatsOxygenGlucoseEndocrinologyBlood pressureHematocritOncologyHyperglycemiaLactatesArterial bloodJournal of Cancer Research and Clinical Oncology
researchProduct

Extensive Assessment of Blood Glucose Monitoring During Postprandial Period and Its Impact on Closed-Loop Performance.

2017

[EN] Background: Closed-loop (CL) systems aims to outperform usual treatments in blood glucose control and continuous glucose monitors (CGM) are a key component in such systems. Meals represents one of the main disturbances in blood glucose control, and postprandial period (PP) is a challenging situation for both CL system and CGM accuracy. Methods: We performed an extensive analysis of sensor¿s performance by numerical accuracy and precision during PP, as well as its influence in blood glucose control under CL therapy. Results: During PP the mean absolute relative difference (MARD) for both sensors presented lower accuracy in the hypoglycemic range (19.4 ± 12.8%) than in other ranges (12.2…

Blood GlucoseMaleTime FactorsGlucose controlEndocrinology Diabetes and MetabolismSpecial Section: Artificial Pancreas: Models Signals and Control0302 clinical medicineInsulin030212 general & internal medicineContinuous glucose monitoringAccuracymedicine.diagnostic_testContinuous glucose monitoringPostprandial periodSignal Processing Computer-AssistedMiddle AgedPostprandial PeriodINGENIERIA DE SISTEMAS Y AUTOMATICAType 1 diabetesPostprandialTreatment OutcomeClosed-loop controlCardiologyFemaleGlucose monitorsAlgorithmsAdultmedicine.medical_specialtyTransducersBiomedical Engineering030209 endocrinology & metabolismBioengineering03 medical and health sciencesInsulin Infusion SystemsPredictive Value of TestsInternal medicineInternal MedicinemedicineHumansHypoglycemic AgentsBlood glucose monitoringType 1 diabetesbusiness.industryBlood Glucose Self-MonitoringReproducibility of Resultsmedicine.diseaseHypoglycemiaEndocrinologyDiabetes Mellitus Type 1businessClosed loopBiomarkersJournal of diabetes science and technology
researchProduct

The Impact of Amino Acids on Postprandial Glucose and Insulin Kinetics in Humans

2020

Different amino acids (AAs) may exert distinct effects on postprandial glucose and insulin concentrations. A quantitative comparison of the effects of AAs on glucose and insulin kinetics in humans is currently lacking. PubMed was queried to identify intervention studies reporting glucose and insulin concentrations after acute ingestion and/or intravenous infusion of AAs in healthy adults and those living with obesity and/or type 2 diabetes (T2DM). The systematic literature search identified 55 studies that examined the effects of l-leucine, l-isoleucine, l-alanine, l-glutamine, l-arginine, l-lysine, glycine, l-proline, l-phenylalanine, l-glutamate, branched-chain AAs (i.e., l-leucine, l-iso…

Blood GlucoseMaleinsulin secretionobesitymedicine.medical_treatmentAdministration OralReviewType 2 diabetes0302 clinical medicinesystematic reviewInsulinIngestionGlucose homeostasis030212 general & internal medicineInfusions IntravenousNutrition and DieteticsL-ARGININEINTRAVENOUS ARGININEFREE FATTY-ACIDSBLOOD-GLUCOSEdynamicsPostprandial PeriodPostprandialSECRETIONFemaletype 2 diabetesLeucineGROWTH-HORMONElcsh:Nutrition. Foods and food supplyAdultORAL ALANINEmedicine.medical_specialtyMETABOLIC-RESPONSElcsh:TX341-641030209 endocrinology & metabolism03 medical and health sciencesInternal medicinemedicineHumansglucose homeostasisinsulin sensitivityamino acidsbusiness.industryInsulinmedicine.diseaseObesityGlucoseEndocrinologyDiabetes Mellitus Type 2kineticsPLASMA-GLUCAGON RESPONSEtime series dataIsoleucinebusinessFood ScienceINGESTIONNutrients
researchProduct